RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shin Nippon Biomedical Laboratories Stock

Shin Nippon Biomedical Laboratories Employees 2025

Shin Nippon Biomedical Laboratories Employees

985

Ticker

2395.T

ISIN

JP3379950003

WKN

A0BMJN

In 2025, Shin Nippon Biomedical Laboratories employed 985 people, a 0% change from the 985 number of employees in the previous year.

Shin Nippon Biomedical Laboratories Aktienanalyse

What does Shin Nippon Biomedical Laboratories do?

Shin Nippon Biomedical Laboratories Ltd (SNBL) is a Japanese company that was founded in 1957. The company is headquartered in Tokyo, Japan. SNBL is an important player in the research and development industry, offering a wide range of services in the field of biomedical research. SNBL's business strategy is based on providing services to pharmaceutical companies and other medical institutions. The service portfolio includes both the development phase and the approval and post-marketing monitoring of drugs. SNBL offers a comprehensive service in this area, ranging from experimental planning to study implementation, report creation, and results analysis. The company has several geographical offices in Asia, Europe, and America to serve its customers worldwide. SNBL is divided into different divisions specializing in different areas of biomedical research. One important division is the Non-human Primates (NHP) research program. SNBL is able to provide a wide range of NHP species for research, ranging from rhesus monkeys to monkeys from China and Africa. These animals are used for research projects both for drug safety assessment and disease exploration. SNBL is also active in the field of genetic engineering, offering a wide range of services in this area. The company has several cell-based assay systems for drug development and experience in producing recombinant proteins for research. SNBL also offers analysis services for nucleic acids and proteins of all kinds and has extensive expertise in genotyping and gene expression analysis. Another pillar of SNBL's activities is toxicology and safety research. SNBL is a leading provider of toxicology studies, advising its clients on the design of animal safety assessment studies. The company also provides a wide range of non-GLP studies for toxicity evaluations. Additionally, SNBL is able to evaluate the results of toxicology studies and conduct risk analyses for specific products. SNBL also has its own drug development pipeline and has several products in development. One example is Nafamostat Mesilate, a drug being developed for the treatment of acute respiratory distress syndrome and acute pancreatitis. The company works closely with its clients to develop customized solutions for their specific research needs. SNBL's products and services make a significant contribution to the biomedical research industry and have worldwide impact on the healthcare of humans and animals. The company has a long history in the research industry and is recognized as a provider of services for drug development due to its expertise and experience. With its extensive services for biomedical research, SNBL will remain an important player in this field in the future. Shin Nippon Biomedical Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Shin Nippon Biomedical Laboratories's Employee Base

Shin Nippon Biomedical Laboratories's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Shin Nippon Biomedical Laboratories's operational capacity and future potential.

Year-to-Year Comparison

Assessing Shin Nippon Biomedical Laboratories's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Shin Nippon Biomedical Laboratories's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Shin Nippon Biomedical Laboratories’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Shin Nippon Biomedical Laboratories stock

How many employees does Shin Nippon Biomedical Laboratories have this year?

Shin Nippon Biomedical Laboratories has 985 undefined employees this year.

How many employees did Shin Nippon Biomedical Laboratories have compared to the previous year?

Compared to the previous year, Shin Nippon Biomedical Laboratories had 0% more employees.

What impact did the number of employees have on the company Shin Nippon Biomedical Laboratories?

The number of employees has a direct impact on the efficiency and productivity of Shin Nippon Biomedical Laboratories. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Shin Nippon Biomedical Laboratories?

The number of employees can also have an impact on investors of Shin Nippon Biomedical Laboratories, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Shin Nippon Biomedical Laboratories affect the company?

An increase in equity of Shin Nippon Biomedical Laboratories can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Shin Nippon Biomedical Laboratories's equity affect the company?

A reduction in equity of Shin Nippon Biomedical Laboratories can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Shin Nippon Biomedical Laboratories?

Some factors that can influence the equity of Shin Nippon Biomedical Laboratories include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Shin Nippon Biomedical Laboratories so important for investors?

The equity of Shin Nippon Biomedical Laboratories is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Shin Nippon Biomedical Laboratories influence the company?

The number of employees at Shin Nippon Biomedical Laboratories can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Shin Nippon Biomedical Laboratories evolved in recent years?

In recent years, the number of employees at Shin Nippon Biomedical Laboratories has changed by 0.

How many employees does Shin Nippon Biomedical Laboratories currently have?

Shin Nippon Biomedical Laboratories currently has 985 undefined employees.

Why is the number of employees important for investors of Shin Nippon Biomedical Laboratories?

The number of employees is important for investors of Shin Nippon Biomedical Laboratories as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Shin Nippon Biomedical Laboratories take to change the number of employees?

To change the number of employees, Shin Nippon Biomedical Laboratories can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Shin Nippon Biomedical Laboratories pay?

Over the past 12 months, Shin Nippon Biomedical Laboratories paid a dividend of 50 JPY . This corresponds to a dividend yield of about 2.84 %. For the coming 12 months, Shin Nippon Biomedical Laboratories is expected to pay a dividend of 64.78 JPY.

What is the dividend yield of Shin Nippon Biomedical Laboratories?

The current dividend yield of Shin Nippon Biomedical Laboratories is 2.84 %.

When does Shin Nippon Biomedical Laboratories pay dividends?

Shin Nippon Biomedical Laboratories pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Shin Nippon Biomedical Laboratories?

Shin Nippon Biomedical Laboratories paid dividends every year for the past 9 years.

What is the dividend of Shin Nippon Biomedical Laboratories?

For the upcoming 12 months, dividends amounting to 64.78 JPY are expected. This corresponds to a dividend yield of 3.67 %.

In which sector is Shin Nippon Biomedical Laboratories located?

Shin Nippon Biomedical Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shin Nippon Biomedical Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shin Nippon Biomedical Laboratories from 6/1/2025 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2025.

When did Shin Nippon Biomedical Laboratories pay the last dividend?

The last dividend was paid out on 6/1/2025.

What was the dividend of Shin Nippon Biomedical Laboratories in the year 2024?

In the year 2024, Shin Nippon Biomedical Laboratories distributed 50 JPY as dividends.

In which currency does Shin Nippon Biomedical Laboratories pay out the dividend?

The dividends of Shin Nippon Biomedical Laboratories are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shin Nippon Biomedical Laboratories

Our stock analysis for Shin Nippon Biomedical Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shin Nippon Biomedical Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.